U.S. Biopharmaceuticals Contract Manufacturing Market Size & Outlook

The biopharmaceuticals contract manufacturing market in the United States is expected to reach a projected revenue of US$ 19,544.1 million by 2030. A compound annual growth rate of 10.6% is expected of the United States biopharmaceuticals contract manufacturing market from 2025 to 2030.
Revenue, 2024 (US$M)
$10,674.2
Forecast, 2030 (US$M)
$19,544.1
CAGR, 2025 - 2030
10.6%
Report Coverage
U.S.

U.S. biopharmaceuticals contract manufacturing market highlights

  • The U.S. biopharmaceuticals contract manufacturing market generated a revenue of USD 10,674.2 million in 2024 and is expected to reach USD 19,544.1 million by 2030.
  • The U.S. market is expected to grow at a CAGR of 10.6% from 2025 to 2030.
  • In terms of segment, mammalian was the largest revenue generating source in 2024.
  • Non-mammalian is the most lucrative source segment registering the fastest growth during the forecast period.

Biopharmaceuticals contract manufacturing market data book summary

Market revenue in 2024USD 10,674.2 million
Market revenue in 2030USD 19,544.1 million
Growth rate10.6% (CAGR from 2024 to 2030)
Largest segmentMammalian
Fastest growing segmentNon-mammalian
Historical data2018 - 2023
Base year2024
Forecast period2025 - 2030
Quantitative unitsRevenue in USD million
Market segmentationMammalian, Non-mammalian
Key market players worldwideBoehringer Ingelheim, Lonza Group Ltd, Innovent Biologics Inc, Rentschler Biopharma SE, JRS Pharma, AGC Inc, AGC Biologics, Probiogen, FUJIFILM Holdings Corp, Toyobo Co Ltd, Samsung Electronics Co Ltd, Thermo Fisher Scientific Inc, WuXi Biologics (Cayman) Inc, AbbVie Inc, Novartis AG ADR, Catalent Inc, ADMA Biologics Inc, Pfizer Inc, Siegfried Holding AG, Cambrex, Binex

Other key industry trends

  • In terms of revenue, U.S. accounted for 26.6% of the global biopharmaceuticals contract manufacturing market in 2024.
  • Country-wise, U.S. is expected to lead the global market in terms of revenue in 2030.
  • In North America, U.S. biopharmaceuticals contract manufacturing market is projected to lead the regional market in terms of revenue in 2030.
  • Canada is the fastest growing regional market in North America and is projected to reach USD 5,104.4 million by 2030.

No credit card required*

Horizon in a snapshot

  • 30K+ Global Market Reports
  • 120K+ Country Reports
  • 1.2M+ Market Statistics
  • 200K+ Company Profiles
  • Industry insights and more

Biopharmaceuticals Contract Manufacturing Market Scope

Biopharmaceuticals contract manufacturing market segmentation & scope
Mammalian
Non-mammalian
Downstream
Upstream
Fill & Finish Operations
Analytical & QC Studies
Packaging & Labelling
Others
Monoclonal Antibodies (mAbs)
Recombinant Proteins
Vaccines
Antisense, RNAi, & Molecular Therapy
Others
Biosimilars
Drug Substance
Finished Drug Product
Clinical
Commercial
Oncology
Autoimmune Diseases
Infectious Diseases
Cardiovascular Diseases
Metabolic Diseases
Neurology
Others
Countries
Mexico
UK
Italy
Spain
Sweden
Denmark
Norway
Japan
Australia
South Korea
Thailand
Argentina
Saudi Arabia
UAE
Kuwait

Biopharmaceuticals Contract Manufacturing Market Companies

Name Profile # Employees HQ Website

U.S. biopharmaceuticals contract manufacturing market outlook

The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to biopharmaceuticals contract manufacturing market will help companies and investors design strategic landscapes.


Mammalian was the largest segment with a revenue share of 55.22% in 2024. Horizon Databook has segmented the U.S. biopharmaceuticals contract manufacturing market based on mammalian, non-mammalian covering the revenue growth of each sub-segment from 2018 to 2030.


The U.S market for biopharmaceutical manufacturing accounted for significant share in 2021 owing to rising R&D spending for the biologics development coupled with the presence of large number of FDA approved drugs in the country.

Steady growth in the number of new biological approvals in the country is anticipated to boost revenue generation for the U.S. market for biopharmaceutical manufacturing. Increasing adoption and investment in advanced manufacturing technologies by CMOs based in the U.S. is propelling the growth of biopharmaceutical manufacturing market in the country.

Reasons to subscribe to U.S. biopharmaceuticals contract manufacturing market databook:

  • Access to comprehensive data: Horizon Databook provides over 1 million market statistics and 20,000+ reports, offering extensive coverage across various industries and regions.
  • Informed decision making: Subscribers gain insights into market trends, customer preferences, and competitor strategies, empowering informed business decisions.
  • Cost-Effective solution: It's recognized as the world's most cost-effective market research database, offering high ROI through its vast repository of data and reports.
  • Customizable reports: Tailored reports and analytics allow companies to drill down into specific markets, demographics, or product segments, adapting to unique business needs.
  • Strategic advantage: By staying updated with the latest market intelligence, companies can stay ahead of competitors, anticipate industry shifts, and capitalize on emerging opportunities.

Target buyers of U.S. biopharmaceuticals contract manufacturing market databook

  • Our clientele includes a mix of biopharmaceuticals contract manufacturing market companies, investment firms, advisory firms & academic institutions.
  • 30% of our revenue is generated working with investment firms and helping them identify viable opportunity areas.
  • Approximately 65% of our revenue is generated working with competitive intelligence & market intelligence teams of market participants (manufacturers, service providers, etc.).
  • The rest of the revenue is generated working with academic and research not-for-profit institutes. We do our bit of pro-bono by working with these institutions at subsidized rates.

Horizon Databook provides a detailed overview of country-level data and insights on the U.S. biopharmaceuticals contract manufacturing market , including forecasts for subscribers. This country databook contains high-level insights into U.S. biopharmaceuticals contract manufacturing market from 2018 to 2030, including revenue numbers, major trends, and company profiles.

Partial client list

  • logo

U.S. biopharmaceuticals contract manufacturing market size, by source, 2018-2030 (US$M)

U.S. Biopharmaceuticals Contract Manufacturing Market Outlook Share, 2024 & 2030 (US$M)

U.S. biopharmaceuticals contract manufacturing market size, by source, 2018-2030 (US$M)

Sign up - it's easy, and free!

Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our free plan indefinitely.

Explore all plans

Included in Horizon account

  • 30K+ Global Market Reports
  • 120K+ Country Reports
  • 1.2M+ Market Statistics
  • 200K+ Company Profiles
  • Industry insights and more